Clinical Trial Protocol
Iranian Registry of Clinical Trials

07 Nov 2026

Bioequivalence study of Sorafenib 200 mg tablet manufactured by Zistdaru Danesh versus originator brand in healthy volunteers in the fasted condition

Protocol summary

Study aim

Bioequivalence Study of Sorafenib (Soraxha)manufactured by Zistdaru Danesh company versus originator brand (Nexavar) manufactured by Bayer

Design

Bioequivalence study, crossover, single-blinded, 24 healthy volunteers. Simple randomization was used for randomization

Settings and conduct

The study is a single-blinded, cross-over and fasting, and on two series of healthy volunteers. The study will be done in two periods (72h). The interval between these two periods is two weeks. In the first round of the study, the candidates divide into two groups. the first group receives a test tablet and the second group receives a brand tablet. Blood samples are collected immediately before and after drug administration by volunteers. Then, drug extraction is done and samples are ready for analysis. These steps are performed in Radin Laboratory in Tabriz.

Participants/Inclusion and exclusion criteria

Inclusion criteria: General Health (Liver, Heart, and Kidney); Body Mass Index (18-28); Informed consent; age (18-55 years old). Exclusion criteria: smoking; history of cardiovascular disease; history of liver and kidney disease; alcohol and drug addiction; history of allergy to Sorafenib.

Intervention groups

Intervention group 1: Nexavar 200mg tablet as a reference Intervention group 2: Soraxha 200mg as a test

Main outcome variables

Maximum drug concentration, Time to reach maximum drug concentration, Half-life of drug

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200105046010N73**
Registration date: **2023-04-11, 1402/01/22**
Registration timing: **prospective**

Last update: **2023-04-11, 1402/01/22**
Update count: **0**

Registration date

2023-04-11, 1402/01/22

Registrant information

Name

Javad Shokri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3661 4125

Email address

shokri.j@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-04-21, 1402/02/01

Expected recruitment end date

2023-10-22, 1402/07/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title
Bioequivalence study of Sorafenib 200 mg tablet manufactured by Zistdaru Danesh versus originator brand in healthy volunteers in the fasted condition

Public title
Bioequivalence study of Sorafenib 200mg tablet
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
General Health (Liver, Heart, and Kidney) Body Mass Index (18-28) Informed consent Age (18-55 years old)
Exclusion criteria:
Smoking History of cardiovascular disease History of liver and kidney disease Alcohol and drug addiction History of allergy to sorafenib
Age
From **18 years** old to **55 years** old
Gender
Both

Phase
Bioequivalence
Groups that have been masked

- Participant

Sample size
Target sample size: **24**
More than 1 sample in each individual
Number of samples in each individual: **34**
Blood sample
Randomization (investigator's opinion)
Randomized
Randomization description
Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball, poured into a container, and mixed. The balls are then removed randomly from the container and divided in 2 groups of 12 test (A) and reference (B) drug recipients, then in the second phase, groups A and B will be cross-referenced to the test and drug recipients.
Blinding (investigator's opinion)
Single blinded
Blinding description
This study is a single-blinded clinical trial (volunteers). Zistdaru Danesh's Sorafenib and Originator brand capsules are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Tabriz University of Medical Sciences Ethics Committee
Street address
International Relations Office, No 2 Central Building, Tabriz University of Medical Sciences, Golgasht Street,
City
Tabriz
Province
East Azarbaijan
Postal code
5165665931
Approval date
2023-03-06, 1401/12/15
Ethics committee reference number
IR.TBZMED.REC.1402.021

Health conditions studied

1

Description of health condition studied
This study is performed on healthy volunteers.
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
The concentration of the drug in blood
Timepoint
Pre-dose, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 12, 24, 48 and 72 h after drug administration
Method of measurement
Liquid Chromatography Mass-Mass

Secondary outcomes

1

Description
Time to reach maximum blood concentration
Timepoint
After intervention
Method of measurement
The time to reach the maximum drug concentration in blood is recorded

2

Description
Extent of absorption
Timepoint

After intervention

Method of measurement

Calculation of area under curve of concentration -time

Intervention groups

1

Description

Intervention group: single dose, one oral tablet 200mg(Nexavar) manufactured by Bayer, as a reference product

Category

Treatment - Drugs

2

Description

Intervention group: Single dose, one oral Soraxha 200 mg tablet manufactured by Zistdaru Danesh company as test product

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Radin laboratory

Full name of responsible person

Javad Shokri

Street address

No.22, first floor, Azadi alley, Moalem st., Abureihan St

City

Tabriz

Province

East Azarbaijan

Postal code

5154995671

Phone

+98 914 313 5843

Fax

Email

shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Zistdaru danesh Co.

Full name of responsible person

Hooshmand Ilka

Street address

No. 404, 4th floor, Rose mall complex, Kharazi highway

City

Tehran

Province

Tehran

Postal code

1498711347

Phone

+98 21 4231 8100

Email

ilka@Zistdaru.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Zistdaru danesh Co.

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Javad Shokri

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

No 4, 10th Ave. Boostan Street, Roshdieh, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

1476651664

Phone

+98 41 3661 4125

Fax

Email

shokri.j@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Javad Shokri

Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
No 4, 10th Ave. Boostan Street, Roshdieh, Tabriz
City
Tabriz
Province
East Azarbaijan
Postal code
5155935357
Phone
+98 41 3661 4125
Fax
Email
shokri.j@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
No 4, 10th Ave. Boostan Street, Roshdieh, Tabriz
City
Tabriz
Province
East Azarbaijan
Postal code
5155935357
Phone
+98 41 3661 4125
Fax
Email
shokri.j@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
These data are as secure between researchers and related industries.
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available